Authored By: Sarah
11 Jul 2024

 Krabbe Disease Treatment Market Size to grow by USD 405.4 million between 2024-2028

According to a research report “ Krabbe Disease Treatment Market” by Therapy (Anticonvulsants, Muscle relaxants, HSCT, Others) Geography (North America, Europe, Asia, Rest of World (ROW))- Global Forecast to 2028 published by Technavio, the market size is estimated to grow by USD 405.4 million, at a CAGR of  7.08% during the forecast period. The Krabbe disease treatment market is poised for significant expansion due to the designation of specific drugs and biologics for the safe and effective treatment of this rare pediatric disease. The Food and Drug Administration (FDA) offers a priority review program, enabling sponsors to secure approval for a biologic or drug for a rare pediatric disease and receive a priority review voucher. This voucher expedites the review process for subsequent marketing applications of different products. For instance, in January 2016, MN-166 (ibudilast) received a rare pediatric disease designation from the FDA for the treatment of type 1 early infantile Krabbe disease. This designation and the subsequent priority review voucher underscore the market potential for Krabbe disease treatments.

Browse market data tables, figures, and in-depth TOC on “Krabbe Disease Treatment Market” by Therapy (Anticonvulsants, Muscle relaxants, HSCT, Others) Geography (North America, Europe, Asia, Rest of World (ROW)) Global Forecast to 2028. Download Free Sample


By Therapy, the Anticonvulsants segment is projected to dominate the market size in 2024


By Geography, North America  segment is expected to hold the largest market size for the year 2024

In the context of Krabbe Disease treatment, anticonvulsant drugs play a crucial role in managing one of the primary symptoms, which is the occurrence of convulsions or seizures. These seizures result from the severe destruction of myelin, a protective covering of nerve fibers. Given the absence of a cure for Krabbe Disease, the demand for anticonvulsants remains robust to mitigate seizure activity in affected children. Phenobarbital and valproic acid are the most commonly prescribed anticonvulsant medications for pediatric patients. The Krabbe Disease Anticonvulsant market is poised for steady expansion throughout the forecast period due to the persistent need for these medications to control seizures in patients.

North America is forecasted to hold the largest market size by region in 2024

The Krabbe Disease Treatment Market represents a significant business opportunity due to the increasing diagnosis rates and demand for effective therapies. Key players in this market are focusing on developing innovative treatments, such as hematopoietic stem cell transplantation and enzyme replacement therapy, to address the unmet medical needs of patients. The market is expected to grow steadily due to rising awareness and advancements in treatment options.

The Krabbe Disease Treatment Market growth and forecasting report also includes detailed analyses of the competitive landscape of the market growth and forecasting and information about 20 market companies, including:

  • AbbVie Inc.
  • Acorda Therapeutics Inc.
  • GlaxoSmithKline Plc
  • Johnson and Johnson Services Inc.
  • Novartis AG
  • Pfizer Inc.
  • Polaryx
  • Teva Pharmaceutical Industries Ltd.
  • UCB SA

For insights on company offerings- Request a sample report!

Research Analysis Overview

Krabbe Disease, also known as Globoid Cell Leukodystrophy, is a rare and severe genetic disorder that affects the central nervous system (CNS) and myelin production in children. The disease is characterized by loss of hearing, imbalances, seizures, muscle spasms, fever, feeding difficulties, and vomiting. Hospitals play a crucial role in the diagnosis and treatment of Krabbe Disease, providing access to various therapies such as enzyme replacement therapies and gene therapies. Anticonvulsant medications are often used to manage seizures, while supportive care is essential for managing symptoms. Medical science continues to explore novel treatments for Krabbe Disease, including stem cell transplants and innovative gene therapies. Caregivers and patient advocacy groups play a vital role in supporting families affected by this condition. Diagnosis involves a series of tests, including Eye Examination, Nerve Conduction, and Imaging Scans, which are conducted by healthcare professionals. Treatment may also include regular check-ups and monitoring of nerve cells and the brain using advanced medical technologies. The healthcare community remains committed to advancing research and finding effective treatments for Krabbe Disease.

Market Research Overview

Krabbe Disease, a rare genetic ailment affecting the central nervous system, causes muscle weakness, visual loss, trouble walking, and imbalances, among other symptoms. The treatment market for this condition is witnessing significant growth due to ongoing drug discovery and commercialization efforts. Basic science research in medical science laboratories and research centers is leading to the development of novel treatments, including enzyme replacement therapies and gene therapies. Healthcare providers, including hospitals, clinics, and rehabilitation facilities, play a crucial role in the treatment of Krabbe Disease. Ethical considerations are essential in the development and implementation of these therapies, involving caregivers, patient advocacy groups, and healthcare professionals. Standard tools for diagnosis include eye inspections, genetic testing, nerve conduction studies, and imaging scans. Anticonvulsant medications, muscle relaxer drugs, and bone marrow transplantation are common treatments. Late-onset and infantile forms of the disease require different approaches. The therapy market includes hospital pharmacies, e-commerce, and retail pharmacies. Clinical development involves clinical trials, gene technology, and biologics. The patient pool is growing, with infants and children being the most affected. Symptoms include seizures, muscle spasms, fever, feeding difficulties, and vomiting. The condition affects nerve cells in the brain and can lead to loss of sight and hearing. Government funding and support from healthcare providers are essential for the continued development of Krabbe Disease treatments. The market for these therapies is expected to grow as new treatments and technologies emerge.


Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200

Read News Read Less
Interested in this report?
Get your sample now!